Dermata Therapeutics, Inc. Common Stock (DRMA) Stock Price

DRMAStock
$1.3474.95%52W
Market Cap$6.64M
P/E
PEG Ratio
Div yield
Beta0.70

DRMA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-1.19%
Price vs S&P 500 (4W)23.11%
VGM Score33.38

DRMA Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.55-$0.74-34.55%(-$0.19)
Q1 2026-$0.53-$0.48+9.43%(+$0.05)
Q4 2025-$1.54-$1.52+1.30%(+$0.02)
Q3 2025-$1.59-$1.65-3.77%(-$0.06)
Q2 2025-$2.90-$1.66+42.76%(+$1.24)

DRMA Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.14
4.14
4.14
4.14

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
DRMADermata Therapeutics, Inc. Common Stock
D$1.34
LLYEli Lilly & Co.DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
NVONovo-Nordisk A/SBCC$45.61
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69

About Dermata Therapeutics, Inc. Common Stock

Dermata Therapeutics develops OTC dermatology treatments for acne, psoriasis, rosacea, and seborrheic dermatitis. The company is advancing a once-weekly acne treatment leveraging its proprietary Spongilla technology platform for enhanced delivery and patient compliance. Dermata plans to expand Spongilla's application across dermatologic and aesthetic markets, including intradermal delivery of botulinum toxin, providing multiple revenue opportunities.